Aktien Sensor

Ipsen SA, a French pharmaceutical company, has seen its stock price surge to levels above its 52-week high, driven by strategic share buybacks and a stable financial situation.

Ipsen SA has strengthened its leadership team and pipeline with the appointment of a new Executive Vice President and promising data on its drug IQIRVO, positioning the company for sustained growth and success.

Ipsen SA reported a 11.6% sales growth in Q1 2025, driven by strong performance across all therapeutic areas and contributions from products Iqirvo and Bylvay.